ClinicalTrials.gg
Not yet recruitingNCT06477757Updated Jun 27, 2024

Inflammatory Response and Oxidative Stress in Cardiac Surgery: Min. Invasive vs. Conventional Extracorporeal Circulation

An interventional study of Minimally Invasive Extracorporeal Circulation and Conventional Extracorporeal Circulation in Oxidative Stress, Systemic Inflammatory Response Syndrome and Extracorporeal Circulation; Complications, sponsored by University Medical Centre Maribor. Not yet recruiting at 1 site in Slovenia. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-06-27.

Sponsored by University Medical Centre Maribor · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Study summary

The goal of our research project is to measure and compare oxidative stress markers, and systemic inflammatory response in patients undergoing open heart surgery with either conventional or minimally invasive extracorporeal circulation as well as develop pharmacokinetic profiles of different oxidative stress markers for further research on inflammatory response after open heart surgery. The main questions our study aims to answer are :

  • Does the type of extracorporeal circulation affect the levels of different oxidative stress markers?
  • Can preoperative and postoperative oxidative stress marker levels be of prognostic values?
  • Do preoperative and postoperative oxidative stress markers correlate with the clinical outcomes in patients?

Researchers will compare the effect of conventional and minimally invasive extracorporeal circulation on clinical outcomes, oxidative stress marker levels, and systemic inflammatory response.

Participants will be randomised into two groups (one undergoing arrested-heart surgery with the use of conventional extracorporeal circulation, and the second group undergoing arrested-heart surgery with the use of minimally invasive extracorporeal circulation) and laboratory data, oxidative stress markers, and clinical data will be collected until discharge.

Read the detailed description

The overall project objective is to develop an accurate and simple analytical method(s) for quantification of specified oxidative stress biomarkers in biological samples that will provide easier diagnosis, prognosis, and therapeutic design in patients undergoing open heart surgery and a possible comparison between different therapeutic strategies in reducing oxidative stress.

To achieve this goal, the project will be divided into specific objectives:

  • Assortment of specific reactive oxidative species and development of analytical protocols for these oxidative stress biomarkers using sophisticated analytical equipment.
  • Quantification of specific oxidative stress biomarkers as indicators for oxidative stress before and after open heart surgery with the use of cardiopulmonary bypass.
  • Prediction of the level of oxidative stress with specific oxidative stress biomarkers in patients undergoing arrested-heart cardiopulmonary bypass surgery
  • Statistical processing of the obtained data and implementation in clinical practice tailoring the extracorporeal circulation to an individual patient.
  • Comparison of oxidative stress in patients undergoing open-heart surgery with the use of two different types of cardiopulmonary bypass techniques.

State-of-the-art in the proposed field of research and survey of the relevant literature Recent studies on oxidative stress status have identified biomarkers as the potential to revolutionise medical science in terms of diagnosis, prognosis, and therapy. Biomarkers have been identified for various diseases and disorders, for example, metabolic disorders, cardiovascular disease, myocardial infarctions, neurological disorders, etc. The specific biomarkers can help in diagnosing the stress when the prognostic biomarkers are being explored for studying the progression or outcome of this stress-disease cascade and can predict the likelihood of occurrence of disease. Recently, many authors published reviews on oxidative stress and its biomarkers, as well as their quantitative determination, there are also some clinical studies, but often these involve one type of biomarker. Determination of these compounds from serum and plasma is challenging for every analytical technique and requires special precautions at the pre-analytical stage. Recently, various chromatographic methods have been used for substituting conventional spectrophotometric methods. So far, high pressure liquid chromatography (HPLC), liquid chromatography with tandem mass spectrometry (LC-MS/MS) and gas chromatography-mass spectrometry (GC-MS) methods have proven to be specific and more sensitive for most oxidative stress (OS) biomarkers from biological material, but there is still no method that is specific, accurate, sensitive and quantitative enough to measure biomarkers in biological samples and can be used in clinical diagnostics. Since the identification of biomarkers is more reliable, more correlations to certain diseases or disorders can be done, especially in the field of cardiovascular diseases, where the literature is scarce or non. In this study, robust and specific analytical methods for specific OS biomarkers will be developed and validated, therefore understanding the mechanisms and timeline of OS biomarker levels after cardiac surgery.

Cardiopulmonary bypass has been identified as an independent factor for systemic inflammatory response, which potentially leads to hemodynamic instability, multiple organ dysfunction and various complications resulting in a prolonged intensive care unit (ICU) and hospital stay. One of the strategies to reduce the inflammatory response has been MiECC. Regarding to the Minimal invasive Extra-Corporeal Technologies international Society (MiECTiS) to characterise a circuit as MiECC it must include a closed circuit; biologically inert blood contact surfaces; reduced priming volume; a centrifugal pump; a membrane oxygenator; a heat exchanger; a system for cardioplegia delivery; a venous bubble trap/venous air removing device and a shed blood management system. Several studies have been published, measuring and comparing the inflammatory response in patients undergoing open heart surgery with either conventional cardiopulmonary bypass (CCPB) or MiECC. Recent studies, comparing MiECC group to conventional CPB showed lower C-reactive protein (CRP) and interleukin 6 and interleukin 8 levels in the MiECC group. A study, measuring oxidative stress markers in patients who underwent coronary artery bypass surgery with either MiECC, CCPB, or without the use of extracorporeal circuit (off-pump coronary artery bypass - OPCAB) revealed statistically significant decrease in malondialdehyde levels in MiECC and OPCAB when compared to CCPB, which showed promising results on 30 patients included in their study. Also malondialdehyde levels peak after a couple of hours after the surgery, thus making the comparison of immune response to MiECC or CCPB even more interesting. By increasing the number of blood samples, a bigger study cohort and novel techniques of malondialdehyde analysis, the investigators believe that potential prognostic values could be identified. In recent years isoprostane has been identified as a promising biomarker of lipid peroxidation. In a recent study in children with congenital heart defects undergoing cardiac surgery, a rapid clearance of isoprostanes was associated with a better clinical outcome. No studies up to date comparing the results of isoprostanes in patients undergoing CCPB or MiECC have been found. Endocan, a potential immunoinflammatory marker, which reflects endothelial dysfunction, could also be used as a potential prognostic marker for identifying groups of patients who would benefit most from MiECC. Up to date, two studies studying the kinetics of endocan after CCPB have been performed. Comparing our results to other studies and adding MiECC to the equation could prove helpful to future studies using endocan as a prognostic marker.

IMPORTANCE OF THE EXPECTED RESULTS:

The research project entitled Oxidative stress and systemic inflammatory response after cardiac surgery: minimally invasive extracorporeal circulation vs. conventional extracorporeal circulation will efficiently contribute to the improvement of the quality of life since its focus will be on the detection of specific OS biomarkers and understanding the mechanisms and timeline of OS biomarker levels after cardiac surgery. To the investigators knowledge, this will be the first such comprehensive study that will include several biomarkers in the prediction of the level of oxidative stress in patients undergoing arrested-heart cardiopulmonary bypass surgery and compare two types of cardiopulmonary bypass circuits. To establish this prediction, OS biomarkers will be quantified using different chromatographic methods in tandem with mass spectrometry for the selective and efficient determination of these biomarkers. Developed and validated analytical methods will be robust and efficient for method transfer in a clinical environment. Obtained data will be statistically processed and implemented in clinical practice tailored to the extracorporeal circulation of individual patient.

02

Conditions studied

  • Oxidative Stress
  • Systemic Inflammatory Response Syndrome
  • Extracorporeal Circulation; Complications

Keywords

  • Cardiac Surgery
  • Minimally invasive extracorporeal circulation
  • Cardiopulmonary bypass
  • Oxidative Stress
  • Systemic Inflammatory Response Syndrome
  • Oxidative stress biomarkers
  • Malondialdehyde
  • Endocan
03

In context

Systemic Inflammatory Response Syndrome

195 studies on the registry are indexed under Systemic Inflammatory Response Syndrome; 24 are open to participants now.

This study's planned enrollment of 200 is above the median of 76 across 98 interventional studies indexed under Systemic Inflammatory Response Syndrome.

Browse Systemic Inflammatory Response Syndrome studies →

Lead sponsor

University Medical Centre Maribor is the lead sponsor of 36 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients undergoing elective isolated coronary artery bypass grafting (CABG) with the use of cardio-pulmonary bypass (CPB) through median sternotomy with central cannulation

Exclusion Criteria Before Enrollment:

  • refusal to participate in the study,
  • pregnant women,
  • patients with previous cardiac surgery (i.e., redo surgery),
  • emergency surgery,
  • patients with known allergy to any drugs used in the study protocol except cefazolin.

Exclusion Criteria After Enrollment:

  • Patients in whom intraoperative transesophageal echocardiogram (TEE) would show an atrial septal defect, where additional procedures would be needed intraoperatively or a conversion from MiECC to conventional extracorporeal circulation would be needed.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Conventional Extracorporeal Circulation Arm (CCPB Arm)

    Patients randomized into this group will be undergoing arrested-heart coronary artery bypass grafting with the use of conventional extracorporeal circulation.

    Procedure: Conventional Extracorporeal Circulation

  • Experimental
    Minimally Invasive Extracorporeal Circulation Arm (MiECC Arm)

    Patients randomized into this group will be undergoing arrested-heart coronary artery bypass grafting with the use of minimally invasive extracorporeal circulation.

    Procedure: Minimally Invasive Extracorporeal Circulation

Interventions

  • ProcedureMinimally Invasive Extracorporeal Circulation

    Clinical outcomes, oxidative stress marker levels comparison in patients undergoing open-heart surgery with minimally invasive extracorporeal circulation.

  • ProcedureConventional Extracorporeal Circulation

    Clinical outcomes, oxidative stress marker levels comparison in patients undergoing open-heart surgery with either conventional extracorporeal circulation.

06

What researchers measure

Primary outcomes

  1. Oxidative stress biomarker levels

    Oxidative stress biomarker levels will be analyzed from blood samples collected at predetermined time-frames.

    Time frame: From enrollment until discharge, assessed up to 100 weeks.

Secondary outcomes

  1. Incidence of postoperative atrial fibrillation

    Atrial fibrillation will be monitored by continuous telemetry following cardiac surgery, until discharge.

    Time frame: From enrollment until discharge, assessed up to 100 weeks.

  2. Incidence of postoperative acute kidney failure

    Kidney function will be monitored by measuring urine secretion and glomerular filtration rate at predetermined time frames, and evaluated according to Kidney Disease: Improving Global Outcomes (KDIGO) system.

    Time frame: From enrollment until discharge, assessed up to 100 weeks.

07

Study locations

1 site
  • UMC Maribor
    Maribor, Slovenia
    • Rebe Petrovic, MD · Contactrene.petrovic@gmail.com · +38640556570
    • Miha Antonic, MD, PhD · Contactmiha.antonic@guest.arnes.si
    • Anze Djordjevic, MD, PhD · Sub investigator
    • Jernej Zeleznik, MD · Sub investigator
    • Urska Intihar, MD · Sub investigator
    • Peter Juric, MD · Sub investigator
    • Boris Robic, MD · Sub investigator
    • Franc Gregorcic, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — After the study, approximately in 2026.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After the study, approximately in 2026.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2024; primary completion for Dec 2025, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2024
First posted
Jun 27, 2024
StartEst.
Jul 29, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2026
Last update
Jun 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06477757
Lead sponsor
University Medical Centre Maribor
Responsible party
Rene Petrovic (Principal Investigator, University Medical Centre Maribor) — Principal investigator
First posted
Jun 27, 2024
Start date
Jul 29, 2024 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 27, 2024

Study contacts

Rene Petrovic, MD
Contact
rene.petrovic@gmail.com
+38640556570
Miha Antonic, MD, PhD
Contact
miha.antonic@guest.arnes.si
Rene Petrovic, MD
principal investigator · UMC Maribor
Petra Kotnik, PhD
principal investigator · University of Maribor
Miha Antonic, MD, PhD
principal investigator · UMC Maribor

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion